Digitalis Update
- 1 January 1981
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 141 (1) , 17-18
- https://doi.org/10.1001/archinte.1981.00340010019004
Abstract
Are physicians prematurely condemning digitalis because the "drug lag" has created a hunger for new cardiovascular agents? Advances in clinical science do require continued refinement of indications and use of the digitalis glycosides. The classic indication for universal prescription, "congestive heart failure," must be more finely tuned.1 When the etiologic determinants of failure are pulmonary, endocrine, hypertension, mechanical, or muscle replacement, considerable evidence indicates that digitalis will be slightly effective or ineffective. But when affliction of left ventricular myocardium is the principal culprit, the weight of scientific evidence supports the therapeutic efficacy of the digitalis glycosides.2 Studies not yet carried out will compare the relative merits of other modes of therapy with digitalis for immediate and long-term effects, morbidity, and mortality. Afterload reduction has been impressive, particularly in subsets of patients shown to respond poorly to digitalis therapy. Whether these new agents will be as convenient and effectiveThis publication has 6 references indexed in Scilit:
- Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxicationThe American Journal of Cardiology, 1978
- Current Considerations in Digoxin UsageCRC Critical Reviews in Clinical Laboratory Sciences, 1978
- Digitalis toxicity: Epidemiology and clinical use of serum concentration measurementsThe American Journal of Medicine, 1975
- Serum digoxin levels using an 125I-labelled antigen: Validation of method and observations on cardiac patientsAmerican Heart Journal, 1975
- Assays of digitalis in the bloodProgress in Cardiovascular Diseases, 1972
- Introduction of Digitalis into North AmericaNew England Journal of Medicine, 1946